The ARRIVE trial evaluated elective induction of labour at 39 weeks compared to expectant management. Its main finding was:
- A Elective induction at 39 weeks significantly increased cesarean delivery rates
- B Elective induction at 39 weeks increased neonatal morbidity
- C Elective induction at 39 weeks reduced perinatal mortality and reduced cesarean delivery rates ✓
- D Elective induction at 39 weeks had no effect on any maternal or fetal outcome
Correct answer: C. Elective induction at 39 weeks reduced perinatal mortality and reduced cesarean delivery rates
Explanation
The ARRIVE trial (2018) randomized low-risk nulliparous women at 39 weeks to elective induction versus expectant management. Contrary to prior belief, induction of labour at 39 weeks did not increase cesarean delivery rates (18.6% vs 22.2%, significantly lower) and was associated with reduced perinatal mortality and morbidity. This landmark trial changed clinical practice; elective induction at 39 weeks in low-risk nulliparas is now supported by evidence and offered in many centers.
Reference: Williams Obstetrics, 26th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.